Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial

[1]  Ludwig Kappos,et al.  Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring , 2007, The Lancet Neurology.

[2]  A. Berrebi,et al.  Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial , 2010, The Lancet.

[3]  P. Calabresi,et al.  Abnormal B‐cell cytokine responses a trigger of T‐cell–mediated disease in MS? , 2010, Annals of neurology.

[4]  Ludwig Kappos,et al.  Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. , 2010, The New England journal of medicine.

[5]  P. Vermersch,et al.  A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. , 2010, The New England journal of medicine.

[6]  Ludwig Kappos,et al.  A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. , 2010, The New England journal of medicine.

[7]  G. Fingerle-Rowson,et al.  Addition of rituximab to fl udarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia : a randomised , open-label , phase 3 trial , 2010 .

[8]  K. Selmaj,et al.  Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. , 2008, The New England journal of medicine.

[9]  D. Bourdette,et al.  B-cell depletion with rituximab in relapsing-remitting multiple sclerosis , 2008, Current neurology and neuroscience reports.

[10]  M. Genovese,et al.  Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study. , 2008, Arthritis and rheumatism.

[11]  Stephen L. Hauser,et al.  The genetics of multiple sclerosis: SNPs to pathways to pathogenesis , 2008, Nature Reviews Genetics.

[12]  D. Arnold,et al.  B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. , 2008, The New England journal of medicine.

[13]  E. Kimby,et al.  Interim Results of a Phase I/II Study of Ocrelizumab, a New Humanised Anti-CD20 Antibody in Patients with Relapsed/Refractory Follicular Non-Hodgkin’s Lymphoma. , 2007 .

[14]  Bernhard Hemmer,et al.  Early MRI changes in a mouse model of multiple sclerosis are predictive of severe inflammatory tissue damage. , 2007, Brain : a journal of neurology.

[15]  L. Kappos,et al.  Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring , 2007, The Lancet Neurology.

[16]  M. Duddy,et al.  Distinct Effector Cytokine Profiles of Memory and Naive Human B Cell Subsets and Implication in Multiple Sclerosis , 2007, The Journal of Immunology.

[17]  L. Klareskog,et al.  Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE. , 2007, Clinical immunology.

[18]  A. Cabral,et al.  Autoimmune inflammation from the Th17 perspective. , 2007, Autoimmunity reviews.

[19]  M. Duddy,et al.  B-cells in multiple sclerosis. , 2006, International MS journal.

[20]  Michael J. Ramsbottom,et al.  Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients , 2006, Journal of Neuroimmunology.

[21]  Ludwig Kappos,et al.  Oral fingolimod (FTY720) for relapsing multiple sclerosis. , 2006, The New England journal of medicine.

[22]  V. Kuchroo,et al.  Myelin oligodendrocyte glycoprotein-specific T and B cells cooperate to induce a Devic-like disease in mice. , 2006, The Journal of clinical investigation.

[23]  Stanley B. Cohen,et al.  Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. , 2006, Arthritis and rheumatism.

[24]  M. Krumbholz,et al.  B lineage cells in the inflammatory central nervous system environment: Migration, maintenance, local antibody production, and therapeutic modulation , 2006, Annals of neurology.

[25]  P. Emery,et al.  The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. , 2006, Arthritis and rheumatism.

[26]  B. Serafini,et al.  B-cell differentiation in the CNS of patients with multiple sclerosis. , 2005, Autoimmunity reviews.

[27]  E. Frohman,et al.  Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis. , 2005, Archives of neurology.

[28]  B. Serafini,et al.  Detection of Ectopic B‐cell Follicles with Germinal Centers in the Meninges of Patients with Secondary Progressive Multiple Sclerosis , 2004, Brain pathology.

[29]  A. Compston,et al.  Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis , 2001, Annals of neurology.

[30]  S. Hauser,et al.  Identification of autoantibodies associated with myelin damage in multiple sclerosis , 1999, Nature Medicine.

[31]  J. Kurtzke.  Rating neurologic impairment in multiple sclerosis , 1983, Neurology.